Serplulimab Combined With Nab-paclitaxel and Cisplatin in Neoadjuvant Therapy for Resectable Esophageal Squamous Cell Carcinoma

NCT06388135 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

80

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Serplulimab Combined With Nab-paclitaxel and Cisplatin
DRUG: nab-paclitaxel，Cisplatin

Sponsor

Yang Jianjun, PhD